AbbVie Inc (ABBV)vsMeihua International Medical Technologies Co Ltd (MHUA)
ABBV
AbbVie Inc
$246.12
+0.98%
HEALTHCARE · Cap: $430.82B
MHUA
Meihua International Medical Technologies Co Ltd
$7.61
0.00%
HEALTHCARE · Cap: $425.43M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 71801% more annual revenue ($64.39B vs $89.55M). MHUA leads profitability with a 10.3% profit margin vs 9.8%. MHUA trades at a lower P/E of 0.3x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
MHUA
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-63.1%
Fair Value
$150.90
Current Price
$246.12
$95.22 premium
Intrinsic value data unavailable for MHUA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Revenue declined 16.2%
Earnings declined 42.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : MHUA
The strongest argument for MHUA centers on P/E Ratio, Price/Book, Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Bear Case : MHUA
The primary concerns for MHUA are Market Cap, Piotroski F-Score, Revenue Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while MHUA is a declining play — different risk/reward profiles.
MHUA carries more volatility with a beta of 0.75 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 34/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Meihua International Medical Technologies Co Ltd
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Meihua International Medical Technologies Co., Ltd. is engaged in the manufacturing and marketing of medical consumables in the People's Republic of China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?